New hope for kids with retinoblastoma: tailored therapies aim to save lives and sight

NCT ID NCT00186888

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested personalized treatments for children with retinoblastoma, a rare eye cancer. Researchers divided 107 participants into groups based on whether one or both eyes were affected and how advanced the cancer was. They used combinations of chemotherapy drugs like vincristine, carboplatin, and topotecan, along with surgery if needed, aiming to cure the cancer while preserving vision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vincristine, Carboplatin, Topotecan
What this could lead to
If successful, this study could improve how doctors personalize treatment for children with retinoblastoma, potentially increasing cure rates and saving more vision.
What could go wrong
This is an older completed study, so results may not reflect current best practices. Chemotherapy has side effects like infection risk and organ damage, and some children may still need eye removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAOCULAR RETINOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.